Pharmafile Logo
Pharmafocus logo
Advanced Search

Cancer

Showing 15 posts of 1067 posts found.

Tarceva image

NICE no for first line Tarceva

February 17, 2012
Sales and Marketing CDF, Cancer, NICE, Roche, Tarceva

NICE no for first line Tarceva Watchdog wants more information on Roche’s drug NICE is not recommending Roche’s lung cancer …

News
Boehringer picture

Boehringer broadens afatinib studies

January 27, 2012
Research and Development, Sales and Marketing Boehringer Ingelheim, Cancer, afatinib

Boehringer Ingelheim is expanding the scope of its studies into afatinib to test its use against head and neck cancers. …

News
Avastin picture

Avastin now available in UK for ovarian cancer

January 17, 2012
Sales and Marketing Cancer, Cancer Drugs Fund, NICE, Roche, avastin

Roche’s Avastin is now available as a treatment for women with ovarian cancer in the UK. Avastin (bevacizumab) can now …

News

Lilly teams up with ImmunoGen on antibody-drug conjugates

December 21, 2011
ADC, Cancer, Immunogen, T-DM1, conjugate, lilly, oncology

ImmunoGen has signed a new collaboration with Eli Lilly to develop antibody-drug conjugate for cancer treatments.Lilly will pay an upfront …

News

New cancer drug costs escalating for NHS

December 13, 2011
Cancer, NHS, oncology

New oncology drugs are pushing up the overall costs of treating cancer, according to a new report. The ‘Cancer Diagnosis …

News

No cancer link with Lantus, says Sanofi

December 7, 2011
Sales and Marketing Cancer, Lantus, Sanofi, diabetes, insulin, safety

Sanofi has presented a new meta-analysis which suggests its insulin blockbuster Lantus does not raise the risk of cancer. A …

News
Abbott picture

Abbott expands diagnostic pact with GlaxoSmithKline

November 29, 2011
Research and Development, Sales and Marketing Abbott, Cancer, GSK, non-small cell lung cancer

Abbott will develop a diagnostic kit for GlaxoSmithKline’s new lung cancer drug candidate.   This is an expansion of a …

News

Pancreatic cancer sees lowest improvement in cancer survival

November 23, 2011
Medical Communications, Research and Development Cancer, Macmillan, pancreatic

A new cancer survival study shows that pancreatic cancer continues to have one of the worst mortality rates.  The study …

News

Aslan licences promising cancer drug from Bristol-Myers Squibb

November 7, 2011
Research and Development, Sales and Marketing Aslan, BMS, Cancer

Bristol-Myers Squibb has licensed one of its investigational oncology compounds, for the treatment of multiple solid tumours, to Singapore-based Aslan …

News

NICE blames pharma R&D model for spiralling cancer drug costs

September 29, 2011
Research and Development, Sales and Marketing Cancer, NICE, clincial trials

NICE has blamed the pharma industry’s ‘inefficient’ and increasingly costly R&D model for the rising price of cancer drugs. NICE …

News

Cancer costs on an ‘unaffordable trajectory’

September 28, 2011
Sales and Marketing Cancer, healthcare costs

The cost of cancer is rising too fast with new treatments giving uncertain benefits, according to a new study. A …

News

Roche to show new cancer data at European congress

September 20, 2011
Research and Development Cancer, Roche, T-DM1, Zelboraf, avastin

Roche will highlight a range of new approaches in targeting cancer at the upcoming European cancer conference. In a series …

News

GSK-Merck back new developing world cancer charity

September 14, 2011
Medical Communications Cancer, GSK, Merck & Co, Pink Ribbon-Red Ribbon, breast cancer, cervical cancer

GlaxoSmithKline and Merck are among the backers of a new charity that focuses on preventing female cancers in developing countries. …

News
US Food and Drug Administration

FDA unveils changes to cancer drug review

September 14, 2011
Research and Development, Sales and Marketing Cancer, FDA, regulatory affairs

The FDA has unveiled a reorganisation of how it reviews new cancer drugs, and says the new approach should help …

News

Blood cancer drug Adcetris approved by FDA

August 24, 2011
Sales and Marketing Adcetris, Cancer, Seattle Genetics, lymphoma

The FDA has approved Seattle Genetics’ blood cancer drug Adcetris for two forms of lymphoma. Adcetris (brentuximab vedotin) can now …

News
The Gateway to Local Adoption Series

Latest content

Just – Evotec given Gates Foundation grant to increase global biotherapeutics access

January 8, 2026

Johnson & Johnson submits robotic surgical system for De Novo classification

January 8, 2026

EA Pharma announces phase 3 trial for new schizophrenia treatment in Japan

January 7, 2026

Eleva appoints Erich Rajkovic as Chief Business Officer

January 7, 2026

MedPharm announces US FDA inspection of North Carolina manufacturing facility

January 6, 2026